Improved prognosis of de novo metastatic prostate cancer after an introduction of life-prolonging agents for castration-resistant prostate cancer

Tokiyoshi Tanegashima(Chiba Cancer Center), Takuma Kato(Kagawa University), Naoki Terada(Tohoku University), Masaki Shiota(Kyushu University), Yasuhiro Hashimoto(Hirosaki University), Kentaro Kuroiwa(Miyazaki Prefectural Hospital), Shinichi Sakamoto(Chiba University), Toru Shimazui(University of Tsukuba), Ken‐ichi Tabata(Kitasato University), Sadafumi Kawamura(Miyagi Prefectural Hospital Organization), Masatoshi Eto(Kyushu University), Naoki Kohei(Shizuoka General Hospital), Akira Yokomizo(Kyushu University), Shogo Teraoka(Tottori University Hospital), Hideki Enokida(Kagoshima University Hospital), Hiroaki Matsumoto(Yamaguchi University), Shintaro Narita(Akita University), Masashi Kato(Nagoya University), Yoshiyuki Nagumo(University of Tsukuba Hospital), Koji Mitsuzuka(Pacific Northwest Diabetes Research Institute), Ryotaro Tomida(Shikoku Cancer Center), Nobumichi Tanaka(Nara Medical University), Takahiro Osawa(Hokkaido University), Kohei Hashimoto(Sapporo Medical University), Toshihiro Saito, Toshihiko Sakurai(Sojo University), Takayuki Goto(Kyoto University), Atsushi Takahashi(Fukushima Medical University), Hiroaki Yasumoto(Shimane University), Takahiro Kimura(Jikei University School of Medicine), Hiroshi Kitamura(University of Toyama), Manabu Kamiyama(University of Yamanashi Hospital), Toshiyuki Kamoto(Kyoto University), Takayuki Sugiyama(Hamamatsu University)
International Journal of Clinical Oncology
December 17, 2024
Cited by 0


Related Papers